--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-22-308415" form_type: "8-K" ticker: "INTI" cik: "0001042418" company_name: "Inhibitor Therapeutics, Inc." filed_at: "2022-12-19T23:59:59+00:00" generated_at: "2026-06-21T02:19:39.317977+00:00" event_type: "litigation" sentiment: "positive" materiality_score: 0.9 calibrated_materiality_score: 0.9 confidence: "high" source: SEC EDGAR --- # Inhibitor Therapeutics settles derivative and class actions, appoints new CEO and board ## Summary - Settlement provides $14.25M cash payment to company from Mayne Pharma's D&O insurance. - Mayne Pharma surrenders all equity and forgives certain debts owed by the company. - Directors and officers resigned; stock options and warrants cancelled. - Francis O'Donnell appointed Executive Chairman and CEO; new board members appointed. - Third Amended Supply and License Agreement terminated; company retains royalty on SUBA-Itraconazole sales. ## SEC filing metadata - accession: 0001193125-22-308415 - form_type: 8-K - ticker: INTI - cik: 0001042418 - company_name: Inhibitor Therapeutics, Inc. - filed_at: 2022-12-19T23:59:59+00:00 - event_type: litigation - sentiment: positive - materiality_score: 0.9 - calibrated_materiality_score: 0.9 - confidence: high - sec_items: 1.01, 1.02, 5.01, 5.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/d428971d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-22-308415 - JSON: https://secwatch.observer/filing/0001193125-22-308415.json - Plain text: https://secwatch.observer/filing/0001193125-22-308415.txt ## Key facts - Executive change Stefan J. Cross resigned as Director at Inhibitor Therapeutics, Inc.. - Action: resigned - Role: Director source text: On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Executive change W. Mark Watson resigned as Director at Inhibitor Therapeutics, Inc.. - Action: resigned - Role: Director source text: On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Executive change Nicholas J. Virca resigned as other_named_officer at Inhibitor Therapeutics, Inc.. - Action: resigned source text: On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Executive change Francis E. O'Donnell, Jr. was appointed as Chief Executive Officer at Inhibitor Therapeutics, Inc.. - Action: appointed - Role: Chief Executive Officer source text: On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Executive change Garrison J. Hasara resigned as other_named_officer at Inhibitor Therapeutics, Inc.. - Action: resigned source text: On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Executive change Robert D. Martin resigned as Director at Inhibitor Therapeutics, Inc.. - Action: resigned - Role: Director source text: On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Executive change Francis E. O'Donnell, Jr. was appointed as Executive Chairman at Inhibitor Therapeutics, Inc.. - Action: appointed - Role: Executive Chairman source text: On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Executive change Dr. R. Dana Ono resigned as Director at Inhibitor Therapeutics, Inc.. - Action: resigned - Role: Director source text: On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - M&A Transactions Inhibitor Therapeutics, Inc. underwent a change of control involving Mayne Pharma Ventures Pty Ltd. (closed 2022-12-13). - Action: change of control - Counterparty: Mayne Pharma Ventures Pty Ltd. - Closing: 2022-12-13 source text: the Board of the Company has concluded that a change of control of the Company occurred on December 13, 2022. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Material Agreements Inhibitor Therapeutics, Inc. terminated Third Amended and Restated Supply and License Agreement with Mayne Pharma Ventures Pty Ltd.. - Action: termination - Agreement: supply - Counterparty: Mayne Pharma Ventures Pty Ltd. source text: Due to the events described in Items 1.01 of this Current Report on Form 8-K, the Company and Mayne Pharma terminated the Third Amended and Restated Supply and License Agreement. evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Material Agreements Inhibitor Therapeutics, Inc. entered into Stipulation and Agreement of Compromise, Settlement, and Release with Mayne Pharma Ventures Pty Ltd., Hedgepath LLC, Samuel P. Sears, and the Individual Defendants valued at $14,250,000 in cash (effective 2022-09-09). - Action: entry - Agreement: settlement - Counterparty: Mayne Pharma Ventures Pty Ltd., Hedgepath LLC, Samuel P. Sears, and the Individual Defendants - Value: $14,250,000 in cash - Effective: 2022-09-09 source text: On September 9, 2022, HPLLC, Sears, the Company, the Individual Defendants and Mayne Pharma entered into a Stipulation and Agreement of Compromise, Settlement, and Release, dated and filed with the Court (together with the exhibits thereto, the “Settlement Agreement”), which the Court approved, and the Settlement Agreement went into effect on December 13, 2022 (the “Effective Date”). evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm - Material Agreements Inhibitor Therapeutics, Inc. entered into License Agreement with Mayne Pharma Ventures Pty Ltd. (effective 2022-12-13). - Action: entry - Agreement: license - Counterparty: Mayne Pharma Ventures Pty Ltd. - Effective: 2022-12-13 source text: Additionally, on the Effective Date, the Company and Mayne entered into a license agreement (the “License Agreement”) pursuant to which the Company grants Mayne a worldwide, royalty-free, nonexclusive, perpetual, irrevocable license to certain of the Company’s Patents (as defined in the License Agreement) to the extent they relate to or have potential application in connection with the Product (as defined in the License Agreement). evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522308415/0001193125-22-308415-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.